| Protect Your Investment: Contact Levi & Korsinsky About the Globus Medical, Inc. (GMED) Investigation |
NEW YORK, NY / ACCESS Newswire / May 16, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Globus Medical, Inc. ("Globus Medical, Inc.") (NYSE:GMED) concerning possible violations of federal securities laws. Globus issued a press release reporting its financial results for the first quarter of 2025 On May 8, 2025. |
accessnewswire.com |
2025-05-16 13:15:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Globus Medical, Inc. - GMED |
NEW YORK, NY / ACCESS Newswire / May 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. ("Globus" or the "Company") (NYSE:GMED). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-05-16 13:00:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds Shareholders of an Investigation into Globus Medical, Inc. (GMED) Regarding Potential Securities Fraud Allegations |
NEW YORK, NY / ACCESS Newswire / May 16, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Globus Medical, Inc. ("Globus Medical, Inc.") (NYSE:GMED) concerning possible violations of federal securities laws. Globus issued a press release reporting its financial results for the first quarter of 2025 On May 8, 2025. |
accessnewswire.com |
2025-05-16 11:30:00 |
Czytaj oryginał (ang.) |
| Globus Medical Announces $500 Million Share Repurchase Program |
AUDUBON, Pa., May 15, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced that its Board of Directors has authorized a share repurchase program of up to $500 million of the Company's outstanding common stock. |
globenewswire.com |
2025-05-15 20:30:00 |
Czytaj oryginał (ang.) |
| GMED ALERT: Ongoing Investigation Into Globus Medical, Inc. - Contact Levi & Korsinsky |
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Globus Medical, Inc. ("Globus Medical, Inc.") (NYSE:GMED) concerning possible violations of federal securities laws. Globus issued a press release reporting its financial results for the first quarter of 2025 On May 8, 2025. |
accessnewswire.com |
2025-05-14 16:15:00 |
Czytaj oryginał (ang.) |
| Medical, Inc. Company Investigated by the Portnoy Law Firm |
Investors can contact the law firm at no cost to learn more about recovering their losses |
globenewswire.com |
2025-05-13 22:28:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Globus Medical, Inc. – GMED |
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. (“Globus” or the “Company”) (NYSE: GMED). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. |
globenewswire.com |
2025-05-13 17:37:00 |
Czytaj oryginał (ang.) |
| GMED Q1 Earnings & Revenues Miss, '25 EPS View Down, Stock Falls |
GMED's first-quarter 2025 weak performance reflects soft Enabling Technology deal closures. |
zacks.com |
2025-05-12 12:26:07 |
Czytaj oryginał (ang.) |
| Globus Medical, Inc. (GMED) Q1 2025 Earnings Call Transcript |
Globus Medical, Inc. (NYSE:GMED ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Brian Kearns - SVP, Business Development & IR Dan Scavilla - President & CEO Keith Pfeil - COO & CFO Conference Call Participants Matt Miksic - Barclays Vik Chopra - Wells Fargo Richard Newitter - Truist Securities Matthew Blackman - Stifel Shagun Singh - RBC Caitlin Cronin - Canaccord Genuity David Saxon - Needham & Company Craig Bijou - Bank of America Merrill Lynch Matt Taylor - Jefferies Operator Welcome to the Globus Medical's First Quarter 2025 Earnings Call. [Operator Instructions]. |
seekingalpha.com |
2025-05-09 02:32:05 |
Czytaj oryginał (ang.) |
| Globus Medical (GMED) Reports Q1 Earnings: What Key Metrics Have to Say |
The headline numbers for Globus Medical (GMED) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-05-08 23:30:39 |
Czytaj oryginał (ang.) |
| Globus Medical (GMED) Lags Q1 Earnings and Revenue Estimates |
Globus Medical (GMED) came out with quarterly earnings of $0.68 per share, missing the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $0.72 per share a year ago. |
zacks.com |
2025-05-08 22:50:46 |
Czytaj oryginał (ang.) |
| Globus Medical Reports First Quarter 2025 Results |
AUDUBON, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2025. |
globenewswire.com |
2025-05-08 20:15:00 |
Czytaj oryginał (ang.) |
| Gear Up for Globus Medical (GMED) Q1 Earnings: Wall Street Estimates for Key Metrics |
Beyond analysts' top -and-bottom-line estimates for Globus Medical (GMED), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025. |
zacks.com |
2025-05-05 14:20:51 |
Czytaj oryginał (ang.) |
| Globus Medical (GMED) Earnings Expected to Grow: Should You Buy? |
Globus Medical (GMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-05-01 15:07:29 |
Czytaj oryginał (ang.) |
| 4 MedTech Stocks Poised to Outshine Q1 Earnings Estimates |
MedTech companies' quarterly results are likely to reflect base business recovery on a year-over-year basis. Let's see how HIMS, GMED, QDRL and HAE are poised ahead of their earnings release. |
zacks.com |
2025-05-01 12:30:38 |
Czytaj oryginał (ang.) |
| Why Globus Medical (GMED) is a Top Growth Stock for the Long-Term |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2025-04-22 14:45:37 |
Czytaj oryginał (ang.) |
| Is the Options Market Predicting a Spike in Globus Medical (GMED) Stock? |
Investors need to pay close attention to Globus Medical (GMED) stock based on the movements in the options market lately. |
zacks.com |
2025-04-22 14:15:36 |
Czytaj oryginał (ang.) |
| Will Globus Medical (GMED) Beat Estimates Again in Its Next Earnings Report? |
Globus Medical (GMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. |
zacks.com |
2025-04-18 17:15:41 |
Czytaj oryginał (ang.) |
| Globus Medical Schedules First Quarter Earnings Release and Conference Call |
AUDUBON, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the first quarter ended March 31, 2025 after the market close on Thursday, May 8, 2025. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. |
globenewswire.com |
2025-04-17 20:30:00 |
Czytaj oryginał (ang.) |
| International Growth Drives GMED Stock Amid Fierce Competition |
Globus Medical is gearing up for a series of product launches throughout the Musculoskeletal portfolio in the coming months of 2025. |
zacks.com |
2025-04-14 17:20:36 |
Czytaj oryginał (ang.) |
| Globus Medical Q4 Earnings & Revenues Top, Margins Expand, Stock Dips |
GMED's fourth-quarter 2024 performance reflects strong synergies from the NuVasive merger. |
zacks.com |
2025-02-21 11:20:34 |
Czytaj oryginał (ang.) |
| Globus Medical, Inc. (GMED) Q4 2024 Earnings Call Transcript |
Globus Medical, Inc. (NYSE:GMED ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Brian Kearns - SVP, Business Development and IR Daniel Scavilla - President and CEO Keith Pfeil - COO and CFO Conference Call Participants Vik Chopra - Wells Fargo Matt Miksic - Barclays David Saxon - Needham & Company Jason Wittes - ROTH Shagun Singh - RBC Caitlin Cronin - Canaccord Genuity Craig Bijou - Bank of America Securities Matthew O'Brien - Piper Sandler Steve Lichtman - Oppenheimer Ryan Zimmerman - BTIG Matthew Blackman - Stifel Operator Welcome to the Globus Medical's Fourth Quarter and Full Year 2024 Earnings Call. This time, all lines will be on mute and a Q&A session will be held after the prepared remarks. |
seekingalpha.com |
2025-02-20 23:54:02 |
Czytaj oryginał (ang.) |
| Globus Medical (GMED) Reports Q4 Earnings: What Key Metrics Have to Say |
While the top- and bottom-line numbers for Globus Medical (GMED) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2025-02-20 22:00:20 |
Czytaj oryginał (ang.) |
| Globus Medical (GMED) Q4 Earnings and Revenues Top Estimates |
Globus Medical (GMED) came out with quarterly earnings of $0.84 per share, beating the Zacks Consensus Estimate of $0.76 per share. This compares to earnings of $0.60 per share a year ago. |
zacks.com |
2025-02-20 20:55:24 |
Czytaj oryginał (ang.) |
| Globus Medical: Q4 Revenue Tops Forecast |
Medical technologies specialist Globus Medical (GMED 0.04%) reported impressive results for the fourth quarter of 2024 on Thursday, Feb. 20. The highlights included adjusted earnings per share (EPS) of $0.84, exceeding the consensus forecast of $0.75, along with revenue that reached $657.3 million, topping expectations by $12.3 million. |
fool.com |
2025-02-20 20:52:03 |
Czytaj oryginał (ang.) |
| Globus Medical Reports Fourth Quarter and Full Year 2024 Results |
AUDUBON, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the fourth quarter and year ended December 31, 2024. |
globenewswire.com |
2025-02-20 18:15:00 |
Czytaj oryginał (ang.) |
| Globus Medical (GMED) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures |
Get a deeper insight into the potential performance of Globus Medical (GMED) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics. |
zacks.com |
2025-02-17 12:20:32 |
Czytaj oryginał (ang.) |
| Globus Medical (GMED) Reports Next Week: Wall Street Expects Earnings Growth |
Globus Medical (GMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-02-13 13:06:36 |
Czytaj oryginał (ang.) |
| Globus Medical Inks $250M Deal to Acquire Nevro: Stock to Gain? |
GMED is set to acquire all shares of Nevro in an all-cash transaction, unlocking new growth opportunities. |
zacks.com |
2025-02-11 11:15:24 |
Czytaj oryginał (ang.) |
| NEVRO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nevro Corp. - NVRO |
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Nevro Corp. (NYSE: NVRO) to Globus Medical, Inc. (NYSE: GMED). Under the terms of the proposed transaction, shareholders of Nevro will receive $5.85 in cash for each share of Nevro that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the. |
businesswire.com |
2025-02-10 14:11:00 |
Czytaj oryginał (ang.) |
| Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients |
AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced they have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, Globus Medical will acquire all shares of Nevro for $5.85 per share. The transaction represents a total equity value of approximately $250 million. |
globenewswire.com |
2025-02-06 11:30:00 |
Czytaj oryginał (ang.) |
| Globus Medical (GMED) is a Top-Ranked Growth Stock: Should You Buy? |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2025-02-05 12:45:38 |
Czytaj oryginał (ang.) |
| Globus Medical Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call |
AUDUBON, Pa., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full-year ended December 31, 2024 after the market close on Thursday, February 20, 2025. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. |
globenewswire.com |
2025-01-30 18:35:00 |
Czytaj oryginał (ang.) |
| Why Globus Medical (GMED) is a Top Momentum Stock for the Long-Term |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-01-23 12:51:16 |
Czytaj oryginał (ang.) |
| Globus Medical Surges 62.1% in a Year: What's Driving the Stock? |
GMED's strong synergies from the NuVasive merger and robust performance in the musculoskeletal solutions space bode well for investors. |
zacks.com |
2025-01-21 11:01:19 |
Czytaj oryginał (ang.) |
| Will Globus Medical (GMED) Beat Estimates Again in Its Next Earnings Report? |
Globus Medical (GMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. |
zacks.com |
2025-01-20 15:16:13 |
Czytaj oryginał (ang.) |
| Here's Why Globus Medical (GMED) is a Strong Growth Stock |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2025-01-20 12:51:26 |
Czytaj oryginał (ang.) |
| GMED Stock Rides on NuVasive Synergy Benefits Amid Macro Issues |
Globus Medical is seeing notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings. |
zacks.com |
2025-01-10 13:26:14 |
Czytaj oryginał (ang.) |
| Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results |
AUDUBON, Pa., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year ending December 31, 2024. The company anticipates fourth quarter 2024 sales of approximately $657.0 million, an increase of 6.6 percent over the fourth quarter 2023 on an as-reported basis. Full year 2024 sales are expected to be approximately $2.52 billion, an increase of 60.6 percent over the prior year on an as-reported basis. |
globenewswire.com |
2025-01-08 18:30:00 |
Czytaj oryginał (ang.) |
| The Law Offices of Frank R. Cruz Continues Its Investigation of Globus Medical, Inc. (GMED) on Behalf of Investors |
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz Continues Its Investigation of Globus Medical, Inc. (GMED) on Behalf of Investors. |
businesswire.com |
2025-01-08 14:10:00 |
Czytaj oryginał (ang.) |
| Why Globus Medical (GMED) is a Top Growth Stock for the Long-Term |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2025-01-02 13:07:57 |
Czytaj oryginał (ang.) |
| 4 Healthcare Stocks Rising More Than 50% in 2024 With Room to Grow |
Medical stocks are expected to reap the benefits of affordable health insurance plans, rising surgeries and widespread adoption of telehealth services in the days ahead. However, inflation and supply-chain woes may act as spoilsport. |
zacks.com |
2024-12-24 12:11:11 |
Czytaj oryginał (ang.) |
| Reasons to Add GMED Stock to Your Portfolio Right Now |
Globus Medical's synergistic merger with NuVasive and a strong liquidity position bring optimism to investors. |
zacks.com |
2024-12-24 10:46:11 |
Czytaj oryginał (ang.) |
| Is Your Portfolio Missing These 5 High-Growth Healthcare Stocks? |
The Healthcare sector sees volume growth and improved occupancy while battling rising medical costs and regulatory uncertainty. |
zacks.com |
2024-12-19 15:57:29 |
Czytaj oryginał (ang.) |
| The Zacks Analyst Blog Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen |
Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen are included in this Analyst Blog. |
zacks.com |
2024-12-12 05:16:11 |
Czytaj oryginał (ang.) |
| 5 Medical Device Stocks That Survived the 2024 Market Volatility |
Here, we discuss five medical device stocks, namely ISRG, GMED, GKOS, VCYT and INGN, which gained in 2024 despite ongoing challenges and provide an attractive investment opportunity for 2025. |
zacks.com |
2024-12-11 10:55:37 |
Czytaj oryginał (ang.) |
| What Makes Globus Medical (GMED) a New Buy Stock |
Globus Medical (GMED) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-12-05 15:01:23 |
Czytaj oryginał (ang.) |
| Globus Medical (GMED) Up 2.1% Since Last Earnings Report: Can It Continue? |
Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-12-05 14:35:53 |
Czytaj oryginał (ang.) |
| Here's Why Globus Medical (GMED) is a Strong Value Stock |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2024-12-02 17:26:19 |
Czytaj oryginał (ang.) |
| 3 Reasons Why Growth Investors Shouldn't Overlook Globus Medical (GMED) |
Globus Medical (GMED) could produce exceptional returns because of its solid growth attributes. |
zacks.com |
2024-11-29 15:46:33 |
Czytaj oryginał (ang.) |
| GMED vs. PEN: Which Stock Should Value Investors Buy Now? |
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity right now? |
zacks.com |
2024-11-29 14:46:29 |
Czytaj oryginał (ang.) |
| GMED Stock Might Rise From the Commercial Launch of Its ExcelsiusHub |
Globus Medical commercially launches ExcelsiusHub navigation system to elevate the standard for freehand navigation. |
zacks.com |
2024-11-25 11:25:30 |
Czytaj oryginał (ang.) |
| Globus Medical Launches ExcelsiusHub™ Navigation System |
AUDUBON, Pa., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced the commercial launch of the ExcelsiusHub™ navigation system. ExcelsiusHub™ joins the expansive ecosystem of Excelsius™ technologies and is designed to elevate the standard for freehand navigation. |
globenewswire.com |
2024-11-22 18:30:00 |
Czytaj oryginał (ang.) |
| Globus Medical, Inc. (GMED) Hit a 52 Week High, Can the Run Continue? |
Globus Medical (GMED) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. |
zacks.com |
2024-11-22 12:16:08 |
Czytaj oryginał (ang.) |
| Globus Medical (GMED) is a Top-Ranked Momentum Stock: Should You Buy? |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2024-11-15 12:51:27 |
Czytaj oryginał (ang.) |
| Why Globus Medical (GMED) is a Top Value Stock for the Long-Term |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2024-11-14 12:46:04 |
Czytaj oryginał (ang.) |
| Is Globus Medical (GMED) a Solid Growth Stock? 3 Reasons to Think "Yes" |
Globus Medical (GMED) possesses solid growth attributes, which could help it handily outperform the market. |
zacks.com |
2024-11-13 15:51:16 |
Czytaj oryginał (ang.) |
| Expanding Global Market, NuVasive Benefits to Aid GMED Stock |
Globus Medical is seeing notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings. |
zacks.com |
2024-11-13 14:05:16 |
Czytaj oryginał (ang.) |
| GMED or SONVY: Which Is the Better Value Stock Right Now? |
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and SONOVA HOLDING (SONVY). But which of these two companies is the best option for those looking for undervalued stocks? |
zacks.com |
2024-11-12 14:45:43 |
Czytaj oryginał (ang.) |
| Globus Medical (GMED) is a Top-Ranked Growth Stock: Should You Buy? |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2024-11-11 12:45:23 |
Czytaj oryginał (ang.) |